| __timestamp | Amicus Therapeutics, Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 505679000 |
| Thursday, January 1, 2015 | 76943000 | 487656000 |
| Friday, January 1, 2016 | 104793000 | 660876000 |
| Sunday, January 1, 2017 | 149310000 | 874278000 |
| Monday, January 1, 2018 | 270902000 | 1431159000 |
| Tuesday, January 1, 2019 | 286378000 | 2386000000 |
| Wednesday, January 1, 2020 | 308443000 | 3137000000 |
| Friday, January 1, 2021 | 272049000 | 4181000000 |
| Saturday, January 1, 2022 | 276677000 | 5562000000 |
| Sunday, January 1, 2023 | 152381000 | 7630000000 |
| Monday, January 1, 2024 | 9748000000 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Genmab A/S and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Genmab A/S has consistently outpaced Amicus Therapeutics, with R&D expenses growing by over 1,400%, reaching a peak in 2023. This surge reflects Genmab's aggressive pursuit of groundbreaking therapies. In contrast, Amicus Therapeutics saw a more modest increase of around 220% over the same period, peaking in 2020.
These trends highlight the varying approaches to innovation within the biotech sector, with Genmab's substantial investments potentially positioning it as a leader in the field. As the industry evolves, these R&D strategies will likely play a crucial role in shaping the future of healthcare innovation.
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Genmab A/S
Biogen Inc. or Genmab A/S: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Genmab A/S and Insmed Incorporated
Research and Development Expenses Breakdown: Genmab A/S vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Genmab A/S vs MorphoSys AG
R&D Spending Showdown: Genmab A/S vs Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for Genmab A/S and Wave Life Sciences Ltd.
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Jazz Pharmaceuticals plc and Amicus Therapeutics, Inc. Allocate Funds
Analyzing R&D Budgets: Grifols, S.A. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.